United Therapeutics Corporation Cost of Goods Sold (Deprecated 2018-01-31)
United Therapeutics Corporation (UTHR) reported Cost of Goods Sold (Deprecated 2018-01-31) of $53.00 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-02-21.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-02-21
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $53.00M, a 86.62% increase year-over-year.
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $19.50M, a 17.37% decline year-over-year.
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $18.90M, a 5.50% decline year-over-year.
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $14.30M, a 1942.86% increase year-over-year.
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $105.70M, a 45.39% increase from fiscal 2016.
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $72.70M, a 5.36% increase from fiscal 2015.
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $69.00M, a 45.19% decline from fiscal 2014.
- United Therapeutics Corporation cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $125.90M, a 3.99% decline from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 12 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $53.00M 10-K · filed 2018-02-21 | $72.50M derived: sum of 2 quarters · filed 2018-02-21 | $91.40M derived: sum of 3 quarters · filed 2018-02-21 | $105.70M 10-K · filed 2018-02-21 | ||||
| 2017-09-30 | $19.50M 10-K · filed 2018-02-21 | $38.40M derived: sum of 2 quarters · filed 2018-02-21 | $52.70M 10-Q · filed 2017-10-25 | $81.10M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2017-06-30 | $18.90M 10-K · filed 2018-02-21 | $33.20M 10-Q · filed 2017-07-27 | $61.60M derived: sum of 3 quarters · filed 2018-02-21 | $85.20M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2017-03-31 | $14.30M 10-K · filed 2018-02-21 | $42.70M derived: sum of 2 quarters · filed 2018-02-21 | $66.30M derived: sum of 3 quarters · filed 2018-02-21 | $86.30M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-12-31 | $28.40M 10-K · filed 2018-02-21 | $52.00M derived: sum of 2 quarters · filed 2018-02-21 | $72.00M derived: sum of 3 quarters · filed 2018-02-21 | $72.70M 10-K · filed 2018-02-21 | ||||
| 2016-09-30 | $23.60M 10-K · filed 2018-02-21 | $43.60M derived: sum of 2 quarters · filed 2018-02-21 | $44.30M 10-Q · filed 2017-10-25 | $69.60M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $20.00M 10-K · filed 2018-02-21 | $20.70M 10-Q · filed 2017-07-27 | $46.00M derived: sum of 3 quarters · filed 2018-02-21 | $52.90M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $700.00K 10-K · filed 2018-02-21 | $26.00M derived: sum of 2 quarters · filed 2018-02-21 | $32.90M derived: sum of 3 quarters · filed 2018-02-21 | $48.90M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $25.30M 10-K · filed 2017-02-22 | $32.20M derived: sum of 2 quarters · filed 2017-02-22 | $48.20M derived: sum of 3 quarters · filed 2017-02-22 | $69.00M 10-K · filed 2018-02-21 | $69.04M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $6.90M 10-K · filed 2017-02-22 | $6.89M 10-Q · filed 2015-10-27 | $22.90M derived: sum of 2 quarters · filed 2017-02-22 | $43.70M 10-Q · filed 2016-10-27 | $43.73M 10-Q · filed 2015-10-27 | $59.49M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-06-30 | $16.00M 10-K · filed 2017-02-22 | $16.06M 10-Q · filed 2015-07-28 | $36.80M 10-Q · filed 2016-07-28 | $36.84M 10-Q · filed 2015-07-28 | $52.59M derived: sum of 3 quarters · filed 2017-02-22 | $93.39M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-03-31 | $20.80M 10-K · filed 2017-02-22 | $20.78M 10-Q · filed 2015-04-28 | $36.59M derived: sum of 2 quarters · filed 2017-02-22 | $77.39M derived: sum of 3 quarters · filed 2017-02-22 | $116.10M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $15.79M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $56.59M derived: sum of 2 quarters · filed 2017-02-22 | $95.30M derived: sum of 3 quarters · filed 2017-02-22 | $125.90M 10-K · filed 2017-02-22 | $125.88M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $40.80M 10-Q · filed 2015-10-27 | $79.51M derived: sum of 2 quarters · filed 2015-10-27 | $110.11M 10-Q · filed 2015-10-27 | $148.89M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $38.71M 10-Q · filed 2015-07-28 | $69.31M 10-Q · filed 2015-07-28 | $108.09M derived: sum of 3 quarters · filed 2016-02-25 | $138.80M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $30.60M 10-Q · filed 2015-04-28 | $69.38M derived: sum of 2 quarters · filed 2016-02-25 | $100.09M derived: sum of 3 quarters · filed 2016-02-25 | $132.41M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $38.78M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $69.49M derived: sum of 2 quarters · filed 2016-02-25 | $101.81M derived: sum of 3 quarters · filed 2016-02-25 | $131.13M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $30.72M 10-Q · filed 2014-10-28 | $63.04M derived: sum of 2 quarters · filed 2014-10-28 | $92.35M 10-Q · filed 2014-10-28 | $130.01M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $32.32M 10-Q · filed 2014-07-29 | $61.63M 10-Q · filed 2014-07-29 | $99.30M derived: sum of 3 quarters · filed 2015-02-24 | $127.27M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $29.31M 10-Q · filed 2014-04-29 | $66.98M derived: sum of 2 quarters · filed 2015-02-24 | $94.95M derived: sum of 3 quarters · filed 2015-02-24 | $124.58M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $37.66M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $65.63M derived: sum of 2 quarters · filed 2015-02-24 | $95.27M derived: sum of 3 quarters · filed 2015-02-24 | $119.30M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $27.97M 10-Q · filed 2013-10-29 | $57.60M derived: sum of 2 quarters · filed 2013-10-29 | $81.63M 10-Q · filed 2013-10-29 | $106.96M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $29.63M 10-Q · filed 2013-07-25 | $53.66M 10-Q · filed 2013-07-25 | $78.99M derived: sum of 3 quarters · filed 2014-02-25 | $101.67M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $24.03M 10-Q · filed 2013-04-25 | $49.36M derived: sum of 2 quarters · filed 2014-02-25 | $72.03M derived: sum of 3 quarters · filed 2014-02-25 | $93.20M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $25.33M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $48.00M derived: sum of 2 quarters · filed 2014-02-25 | $69.17M derived: sum of 3 quarters · filed 2014-02-25 | $88.90M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $22.68M 10-Q · filed 2012-11-01 | $43.84M derived: sum of 2 quarters · filed 2012-11-01 | $63.58M 10-Q · filed 2012-11-01 | $82.11M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $21.16M 10-Q · filed 2012-07-26 | $40.90M 10-Q · filed 2012-07-26 | $59.44M derived: sum of 3 quarters · filed 2013-02-26 | $79.59M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $19.74M 10-Q · filed 2012-04-26 | $19.75M 10-Q · filed 2011-04-28 | $38.27M derived: sum of 2 quarters · filed 2013-02-26 | $58.43M derived: sum of 3 quarters · filed 2013-02-26 | $73.69M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | $18.54M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $38.69M derived: sum of 2 quarters · filed 2013-02-26 | $53.95M derived: sum of 3 quarters · filed 2013-02-26 | $67.67M 10-K · filed 2013-02-26 | $67.72M 10-K · filed 2011-02-24 | |||
| 2010-09-30 | $20.16M 10-Q · filed 2011-10-27 | $20.17M 10-Q · filed 2010-10-28 | $35.42M derived: sum of 2 quarters · filed 2011-10-27 | $49.14M 10-Q · filed 2011-10-27 | $49.18M 10-Q · filed 2010-10-28 | $61.36M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-06-30 | $15.26M 10-Q · filed 2011-07-28 | $15.28M 10-Q · filed 2010-07-28 | $28.98M 10-Q · filed 2011-07-28 | $29.01M 10-Q · filed 2010-07-28 | $41.20M derived: sum of 3 quarters · filed 2012-02-28 | $52.78M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-03-31 | $13.74M 10-Q · filed 2011-04-28 | $25.94M derived: sum of 2 quarters · filed 2012-02-28 | $37.52M derived: sum of 3 quarters · filed 2012-02-28 | $46.53M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2009-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $23.78M derived: sum of 2 quarters · filed 2012-02-28 | $32.80M derived: sum of 3 quarters · filed 2012-02-28 | $40.86M 10-K · filed 2012-02-28 | $40.89M 10-K · filed 2011-02-24 | |||
| 2009-09-30 | $11.58M 10-Q · filed 2010-10-28 | $20.59M derived: sum of 2 quarters · filed 2010-10-28 | $28.66M 10-Q · filed 2010-10-28 | |||||
| 2009-06-30 | $9.02M 10-Q · filed 2010-07-28 | $17.08M 10-Q · filed 2010-07-28 | ||||||
| 2008-12-31 | $26.96M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |